Realizing early treatment benefits in dementia

European Journal of Neurology, Supplement

Volumn 12, Issue 3, 2005, Pages 1-2

  Gauthier, S G ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GLUTAMIC ACID;

ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; FRANCE; HUMAN; HYPERTENSION; MULTIINFARCT DEMENTIA; NEUROPROTECTION; PRIORITY JOURNAL; SYMPOSIUM; SYSTEMATIC REVIEW;

EID: 27144435892     PISSN: 14710552     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01320.x     Document Type: Conference Paper

References (6)

1. Black S, Roman GC, Geldmacher DS et al. (2003). Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34:2323-2330.
2. Bond J, Stave C, Sganga A, O'Connell B, Stanley RL (2005). Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract 59(Suppl. 146):8-14.
3. Francis PT, Nordberg A, Arnold SE (2005). A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 26:104-111.
4. Roman GC (2004). Facts, myths, and controversies in vascular dementia. J Neurol Sci 226:49-52.
5. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG (2004). Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 19:624-633.
6. Wilkinson D, Doody R, Helme R et al. (2003). Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61:479-486.